

Discover & Deliver: 10 COVID Vaccine Candidates are in Late-Stage Clinical Trials

According to the World Health Organization, there are now [10 vaccines](#) in late-stage clinical trials. Last week, Johnson & Johnson and Novavax, two particularly promising candidates, entered or announced the start of Phase 3 clinical trials. They join Moderna, Pfizer, and AstraZeneca that we discussed here last week.

With an increasingly crowded field of Phase 3 vaccines, what is the difference between the candidates?

- **Trial size:** The Johnson & Johnson vaccine will be tested in the largest group to date, with a goal of [enrolling 60,000 people](#). The Novavax vaccine will be tested in 10,000 people in the UK.
- **Dosing:** The Johnson & Johnson vaccine is currently the only single-dose vaccine in the late stages of clinical trials. The Novavax, Pfizer, Moderna, and AstraZeneca all require two doses.
- **Storage:** While the Pfizer and Moderna vaccines must be stored at sub-zero temperatures, both the [Novavax](#) and [Johnson & Johnson](#) vaccine candidates can be stored between 36 and 46 degrees Fahrenheit.

What's next: If the vaccine proves safe and effective, Johnson & Johnson estimates their candidate will be ready for early use authorization (EUA) by early 2021. Similarly, Novavax plans to increase its manufacturing capacity to prepare doses to be distributed by [mid-2021](#).

— Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center